Neos Therapeutics Company Profile (NASDAQ:NEOS)

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

Neos Therapeutics, Inc. (NASDAQ:NEOS) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.83) EPS for the quarter, meeting the consensus estimate of ($0.83). The business had revenue of $4.91 million for the quarter. Neos Therapeutics had a negative return on equity of 611.78% and a negative net margin of 511.74%. View Neos Therapeutics' Earnings History.

Neos Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Neos Therapeutics.

4 brokers have issued 12 month price objectives for Neos Therapeutics' stock. Their predictions range from $12.00 to $20.00. On average, they anticipate Neos Therapeutics' stock price to reach $16.75 in the next year. View Analyst Ratings for Neos Therapeutics.

Here are some recent quotes from research analysts about Neos Therapeutics stock:

• 1. According to Zacks Investment Research, "Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. " (9/12/2017)
• 2. Cantor Fitzgerald analysts commented, "Positives from the quarter: 1) FDA approval of Cotempla XR-ODT in June of this year, with commercial availability in Fall of 2017, 2) On June 27, 2017, Neos announced the pricing of an underwritten public offering of $32.4MM value of common stock at a price of $6.75 per share, before deducting underwriting discounts and commissions and other offering expenses payable by Neos." (8/9/2017)

Some companies that are related to Neos Therapeutics include Corium International (CORI), Teligent (TLGT), Tetraphase Pharmaceuticals (TTPH), Aceto Corporation (ACET), Aquinox Pharmaceuticals (AQXP), Collegium Pharmaceutical (COLL), Allergy Therapeutics plc (AGY), Adamis Pharmaceuticals Corporation (ADMP), BioDelivery Sciences International (BDSI), Marinus Pharmaceuticals (MRNS), Aralez Pharmaceuticals (ARLZ), Diurnal Group PLC (DNL), BioLife Solutions (BLFS), SCYNEXIS (SCYX), Concordia International Corp. (CXRX), Amryt Pharma PLC (AMYT), Evoke Pharma (EVOK) and Juniper Pharmaceuticals (JNP).

Neos Therapeutics' management team includes the folowing people:

• Alan Heller, Chairman of the Board
• Vipin K. Garg Ph.D., President, Chief Executive Officer, Director
• Richard Eisenstadt, Chief Financial Officer
• Dorothy Engelking, Vice President of Regulatory Affairs
• Thomas P McDonnell, Chief Commercial Officer
• Beth P. Hecht, Director
• Paul R. Edick, Non-Executive Director
• Bryant E. Fong, Non-Executive Director
• Gregory J. Robitaille, Non-Executive Director
• John P. Schmid, Non-Executive Director

(NEOS) raised $60 million in an IPO on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Neos Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FLYNN JAMES E (9.08%), Franklin Resources Inc. (9.65%), Vanguard Group Inc. (3.28%), Stonepine Capital Management LLC (2.07%), State Street Corp (1.16%) and Columbus Circle Investors (1.21%). Company insiders that own Neos Therapeutics stock include Alan L Heller, Bryant Fong, Gregory J Robitaille, Juergen Martens, Presidio Partners 2007, LP, Richard I Eisenstadt and Thomas P Mcdonnell. View Institutional Ownership Trends for Neos Therapeutics.

Neos Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including California State Teachers Retirement System and Bank of New York Mellon Corp. View Insider Buying and Selling for Neos Therapeutics.

Neos Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Essex Investment Management Co. LLC, Russell Investments Group Ltd., Columbus Circle Investors, Vanguard Group Inc., DAFNA Capital Management LLC, State Street Corp and Virtu KCG Holdings LLC. Company insiders that have bought Neos Therapeutics stock in the last two years include Alan L Heller, Bryant Fong, Gregory J Robitaille, Juergen Martens, Richard I Eisenstadt and Thomas P Mcdonnell. View Insider Buying and Selling for Neos Therapeutics.

Shares of Neos Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Neos Therapeutics stock can currently be purchased for approximately $8.70.